• Explore /
  • Poster
  • / Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.

Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.

Abstract Poster

Authors

null

Ye Guo

Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China

Ye Guo , Jun Guo , Ying Cheng , Zhen Wang , Yongsheng Li , Dongqing Lv , Yongmei Yin , Guiling Li , Lingying Wu , Yi Huang , Shuqing Wei , Lin Shen , Huaxin Duan , Jiuwei Cui , Hong Luo , Xiumin Li , Kejun Nan , Chunyan Wang , Su-xia Luo , Ruonan Liu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Antibodies

Clinical Trial Registration Number

ChiCTR2000040552

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2536)

DOI

10.1200/JCO.2023.41.16_suppl.2536

Abstract #

2536

Poster Bd #

378

Abstract Disclosures

Similar Posters

First Author: Panpan Zhang

First Author: Gerald Steven Falchook

First Author: Charu Aggarwal

First Author: Omar Saavedra Santa Gadea